Biotrial’s Post

Engineering M13 Bacteriophage for Targeted Photodynamic Cancer Therapy At Targeting Phage Therapy 2024, Alena Kaltenbrunner from the University of Bologna (Alma Mater Studiorum – Università di Bologna), Italy, presented an insightful oral presentation on this topic. She discussed the innovative use of the M13 bacteriophage in targeted photodynamic cancer therapy, highlighting the latest advancements in nanobiotechnology. #PhageTherapy #Nanobiotechnology #CancerTherapy #PhotodynamicTherapy #UniversityofBologna

Please stop by our poster if you attend AACR 2024 in San Diego. This is a great collaboration with NEX-I. The poster will be on April 9 from 9:00 AM to 12:30 PM. Michael Perricone will be available at the conference venue to connect with attendees interested in learning more about our platform. Title: Evaluation of NXI-101 in non-small cell lung cancer (NSCLC) using patient-derived organotypic tumor spheroids (PDOTS): Targeting a novel tumorigenic pathway #AACR #AACR2024 #PDOTS #geneexpression #Immunecontexture #solidtumors #oncology #cancer #tumormicroenvironment #antibody #spheroids #NSCLC

Want to get up to scratch on the latest 3D Cancer Models? Download our whitepaper! 👉 Swipe through to see what you'll learn, including six applications of our 3D tumor modeling capabilities. Explore these applications and other exciting topics in the whitepaper and discover how MIMETAS can help you close the translational gap in cancer drug discovery: https://lnkd.in/eS9r_6-h #CancerResearch #DrugDiscovery #Oncology #OncologyResearch #CancerDrugDiscovery

In this webinar I talk about the power of live-cell imaging for high-throughput tumor organoid drug screening and the pipeline we have established at the UAntwerpen - CORE DrugVision.AI screening facility 🔬, powered by the Orbits Oncology image and data analysis platform 📊. We can now gain insights into: 💊 Drug efficacy, selectivity and mechanism of action 🔍 Predictive biomarkers and signatures 💪 The ideal synergistic co-therapeutic for your drug

Exciting update! Just came across a promising laboratory diagnostic method called NEMO, which has the potential to revolutionize the detection of prostate cancer subtypes. By accurately identifying the tumor fraction and tumor type score, NEMO enables precise differentiation between NEPC and CRPC-CRPC-adeno subtypes. This could be a game-changer in personalized treatment approaches for prostate cancer. Learn more about this groundbreaking development on #PayvandLab website! #ProstateCancer #NEMO #cancerresearch En: https://lnkd.in/dfZ_hR5U Fa: https://lnkd.in/dqJsfKa2

Mouse model of pancreatic cancer👇 Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer “To understand the tumor-initiating potential of Musashi-2 (MSI2+) stem/progenitor cells, we developed a Msi2-CreERT2 knock-in mouse (Msi2CreERT2/+) model in which a CreERT2-cassette was integrated into the “ATG” codon of the Msi2 locus” https://lnkd.in/eibzu4kG

We're heading to Boston this week for the AACR -NCI-EORTC International Conference! Our team is presenting a poster on our collaboration with Ankyra Therapeutics: don't miss it on Thurs 12/10 in Exhibit Hall D! Come join us and discover how Physiomics plc is transforming cancer #drugdevelopment. 🤝 If you're interested in discovering the potential of mathematical modelling and simulation, book a meeting with us at: info@physiomics.co.uk. American Association for Cancer Research #AACR #drugdevelopment #cancerresearch #cancer #oncology #mathematicalmodelling #simulation #insilico #clinicaltrials

A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. An article was recently published in an important journal, highlighting the potential breakthroughs of THIO in lung cancer. Read here: https://lnkd.in/dJC-v8pH #Oncology #OncNews #Science

The Right Cancer Model Makes a Big Difference Searching for the right cancer model for your preclinical study? Our growing collection of richly annotated and low-passage cancer models of patient-consented tumors and cancer cell lines cover 13 different cancer types. Register for access now: https://hubs.ly/Q02lp9xf0. P.S. - We'll be showcasing BarneyOI features at #AACR24. Come by Certis Booth 201! #CancerModels #TumorBank #TumorModels #Biobank #CancerResearch #TranslationalResearch #FightCancer #OncologyIntelligence

If you're attending AACR please swing by our poster presented by the eloquent Eva d'Hennezel and learn more about our first-in-class PIP4K2C degrader!